StocksFundsScreenerSectorsWatchlists
GMTX

GMTX - Gemini Therapeutics, Inc. Stock Price, Fair Value and News

60.88USD+0.22 (+0.36%)Delayed as of 28 Mar 2024, 12:00 pm ET

Market Summary

GMTX
USD60.88+0.22
Delayedas of 28 Mar 2024, 12:00 pm
0.36%

GMTX Alerts

  • Big fall in earnings (Y/Y)
  • Losses in recent quarter

GMTX Stock Price

View Fullscreen

GMTX RSI Chart

GMTX Valuation

Market Cap

1.5B

Price/Earnings (Trailing)

-19.59

Price/Sales (Trailing)

10.81

EV/EBITDA

-14.91

Price/Free Cashflow

-20.36

GMTX Price/Sales (Trailing)

GMTX Profitability

EBT Margin

-55.11%

Return on Equity

-22.15%

Return on Assets

-20.77%

Free Cashflow Yield

-4.91%

GMTX Fundamentals

GMTX Revenue

Revenue (TTM)

138.5M

Rev. Growth (Yr)

711.15%

Rev. Growth (Qtr)

305.61%

GMTX Earnings

Earnings (TTM)

-76.4M

Earnings Growth (Yr)

-109.7%

Earnings Growth (Qtr)

-66.97%

Breaking Down GMTX Revenue

52 Week Range

61.48
(Low)(High)

Last 7 days

-2.1%

Last 30 days

-8.0%

Last 90 days

4.2%

Trailing 12 Months

3629.7%

How does GMTX drawdown profile look like?

GMTX Financial Health

Current Ratio

17.06

GMTX Investor Care

Shares Dilution (1Y)

29.91%

Diluted EPS (TTM)

-3.46

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2023000138.5M
20220000
20210000
20200000

Tracking the Latest Insider Buys and Sells of Gemini Therapeutics, Inc.

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Oct 26, 2022
leonard braden michael
sold
-47,025
2.09
-22,500
-
May 31, 2022
piekos brian
acquired
10,856
1.09
9,960
cfo
Apr 13, 2022
leonard braden michael
bought
291,604
1.5206
191,769
-
Apr 12, 2022
leonard braden michael
bought
75,075
1.365
55,000
-
Apr 12, 2022
leonard braden michael
bought
290,193
1.4243
203,744
-
Apr 11, 2022
leonard braden michael
bought
681,057
1.35
504,487
-
May 14, 2021
meyenburg jason patrick
bought
122,929
9.4561
13,000
president & ceo
May 14, 2021
piekos brian
bought
72,431
9.462
7,655
chief financial officer
Feb 05, 2021
tananbaum james b.
acquired
-
-
2,928,750
-
Feb 05, 2021
tananbaum james b.
acquired
15,000,000
10.00
1,500,000
-

1–10 of 12

Which funds bought or sold GMTX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Nov 14, 2022
Foresite Capital Opportunity Management V, LLC
unchanged
-
-121,000
3,994,000
11.99%
May 16, 2022
Amalgamated Financial Corp.
new
-
4,000
4,000
-%
May 16, 2022
Parametric Portfolio Associates LLC
sold off
-100
-126,000
-
-%

1–3 of 3

Are Funds Buying or Selling GMTX?

Are funds buying GMTX calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own GMTX
No. of Funds

Unveiling Gemini Therapeutics, Inc.'s Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
paradigm biocapital advisors lp
9.9%
2,385,857
SC 13G/A
Feb 13, 2024
bain capital life sciences opportunities iii, lp
5.5%
1,332,545
SC 13G/A
Feb 09, 2024
fmr llc
-
0
SC 13G/A
Feb 07, 2024
adage capital partners gp, l.l.c.
3.11%
750,000
SC 13G/A
Jan 25, 2024
atlas venture fund x, l.p.
5.8%
1,402,186
SC 13D/A
Dec 15, 2023
orbimed advisors llc
7.1%
1,702,237
SC 13D/A
Nov 13, 2023
ai dmi llc
13.74%
3,345,840
SC 13D/A
Sep 25, 2023
paradigm biocapital advisors lp
5.4%
1,235,918
SC 13G
Sep 21, 2023
atlas venture fund x, l.p.
7.0%
1,593,785
SC 13D/A
Jun 30, 2023
adage capital partners gp, l.l.c.
5.24%
1,162,624
SC 13G

Recent SEC filings of Gemini Therapeutics, Inc.

View All Filings
Date Filed Form Type Document
Mar 21, 2024
10-K
Annual Report
Mar 21, 2024
8-K
Current Report
Mar 21, 2024
S-8
Employee Benefits Plan
Mar 07, 2024
4
Insider Trading
Mar 05, 2024
144
Notice of Insider Sale Intent
Mar 05, 2024
144
Notice of Insider Sale Intent
Mar 01, 2024
4
Insider Trading
Mar 01, 2024
4
Insider Trading
Mar 01, 2024
4
Insider Trading
Mar 01, 2024
4
Insider Trading

Gemini Therapeutics, Inc. News

Latest updates
MarketBeat • 25 Mar 2024 • 11:53 pm
MarketBeat • 20 Mar 2024 • 12:41 am

Gemini Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q42023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22020Q42020Q3
Revenue-100.0%-138,508,00034,148,000--------120,750,000
Operating Expenses71.5%29,714,00017,328,00025,125,00015,021,00010,479,00012,015,0009,960,000-20,327,00018,450,00016,320,0009,794,0007,949,000
  S&GA Expenses36.7%7,149,0005,228,0004,945,0005,005,0002,593,0004,301,0002,139,000-9,414,0004,995,0005,478,0002,096,0001,222,000
  R&D Expenses86.5%22,565,00012,100,00020,180,00010,016,0007,886,0007,714,0007,821,000-10,913,00013,455,00010,842,0007,698,0006,727,000
EBITDA Margin-Infinity%-0.55-----------
Interest Expenses-----41,00048,00066,00085,000104,000121,0004,519,0002,047,000
Income Taxes33.3%32,00024,00023,000---------
Earnings Before Taxes-47.9%-23,547,000-15,923,000-22,758,000-11,244,000-16,150,000-9,580,000-9,853,000----311,584-500,911
EBT Margin-Infinity%-0.55-----------
Net Income-47.9%-23,579,000-15,947,000-22,781,000-11,244,000-16,150,000-9,580,000-9,853,00018,077,000-18,551,000-16,447,000-14,315,000-10,003,000
Net Income Margin-Infinity%-0.55-----------
Free Cashflow-39.8%-17,799,000-12,736,000-35,495,000-9,677,000-9,711,000-9,214,000-13,801,00019,491,000----
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q2
Assets-2.3%36837638424420010611312492.00156172189156122-
  Current Assets-2.3%36637438224219810511312490.001551711895.002.00-
    Cash Equivalents-2.7%36137137823619556.0065.0074.0088.0015016818526.0014.006.00
  Net PPE-7.1%0.000.000.000.000.00---0.000.000.000.000.00--
Liabilities30.5%23.0018.0013.0011.0024.001.006.0013.0015.0015.0015.0018.0030.005.00-
  Current Liabilities48.7%21.0014.0010.0010.0023.001.006.0013.0013.0013.0012.0014.0025.001.000.00
Shareholder's Equity-3.9%3453593712331771051071121251411581715.005.000.00
  Retained Earnings-14.3%-188-165-150-135-112-210-207-199-65.39-166-148-131-112-0.500.00
  Additional Paid-In Capital1.9%5345245223682893153143121.0030830630391.006.000.00
Shares Outstanding0.9%24.0024.0023.0020.0017.001.001.001.001.004.004.003.00---
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q1
Cashflow From Operations-138.0%-17,796-7,476-12,724-35,466-9,665-9,692-9,194-13,70119,498-16,097-15,928-15,007-4,539-190-7,033-9,881
  Share Based Compensation51.7%1,9271,2701,3091,024993382382332-5,6071,6592,8621,59359016113894.00
Cashflow From Investing93.3%-3.00-45.00-12.00-29.00-12.00-19.00-20.00-100-7.00120,689----120,750--
Cashflow From Financing1586.5%7,758460153,85577,306148,81522.0086.0055.00-102,730-1,250-1,581195,49070.00122,3789.0020,094

GMTX Income Statement

2023-12-31
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Operating expenses:  
Research and development$ 69,264$ 33,437
General and administrative21,86114,038
Total operating expenses91,12547,475
Loss from operations(91,125)(47,475)
Other income (expense), net:  
Interest income14,797709
Change in fair value of derivative liability0(61)
Other expense(2)0
Total other income (expense), net14,795648
Loss before income taxes(76,330)(46,827)
Income tax expense(99)0
Net loss and comprehensive loss(76,429)(46,827)
Net loss attributable to common stockholders-basic(76,429)(46,827)
Net loss attributable to common stockholders-diluted$ (76,429)$ (46,827)
Weighted-average common shares outstanding-basic22,315,8771,039,490
Weighted-average common shares outstanding-diluted22,315,8771,039,490
Net loss per share attributable to common stockholders-basic$ (3.42)$ (45.05)
Net loss per share attributable to common stockholders-diluted$ (3.42)$ (45.05)

GMTX Balance Sheet

2023-12-31
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 360,382$ 194,611
Prepaid expenses and other current assets5,2803,880
Total current assets365,662198,491
Property and equipment, net170168
Right-of-use assets, operating leases1,9301,430
Other assets234116
Total assets367,996200,205
Current liabilities:  
Accounts payable12,62916,162
Accrued expenses8,1456,109
Operating lease liabilities, current665307
Total current liabilities21,43922,578
Operating lease liabilities, non-current1,4361,027
Total liabilities22,87523,605
Commitments and contingencies (Note 14)
Stockholders' equity:  
Common stock, $0.0001 par value; 100,000,000 shares authorized as of December 31, 2023 and 2022; 24,360,233 and 17,405,231 shares issued as of December 31, 2023 and 2022, respectively; and 24,360,233 and 17,403,315 shares outstanding as of December 31, 2023 and 2022, respectively22
Additional paid-in capital533,764288,814
Accumulated deficit(188,645)(112,216)
Total stockholders' equity345,121176,600
Total liabilities and stockholders' equity$ 367,996$ 200,205
GMTX
0
 WEBSITEwww.geminitherapeutics.com

Gemini Therapeutics, Inc. Frequently Asked Questions


What is the ticker symbol for Gemini Therapeutics, Inc.? What does GMTX stand for in stocks?

GMTX is the stock ticker symbol of Gemini Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Gemini Therapeutics, Inc. (GMTX)?

As of Wed Mar 27 2024, market cap of Gemini Therapeutics, Inc. is 1.5 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of GMTX stock?

You can check GMTX's fair value in chart for subscribers.

What is the fair value of GMTX stock?

You can check GMTX's fair value in chart for subscribers. The fair value of Gemini Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Gemini Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for GMTX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Gemini Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether GMTX is over valued or under valued. Whether Gemini Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Gemini Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for GMTX.

What is Gemini Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Mar 27 2024, GMTX's PE ratio (Price to Earnings) is -19.59 and Price to Sales (PS) ratio is 10.81. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. GMTX PE ratio will change depending on the future growth rate expectations of investors.